SCHEMBL184993

SCHEMBL184993

CCOC(=O)c1ccc(O)c(F)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.72
CA1 P00915 5/20 0.72
CA2 P00918 5/20 0.72
CA7 P43166 5/20 0.72
CA9 Q16790 5/20 0.72
CA14 Q9ULX7 5/20 0.72
HSD17B2 P37059 1/20 0.64
ESR1 P03372 3/20 0.58
ESR2 Q92731 1/20 0.58
LMNA P02545 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
MAOA P21397 1/20 0.51
PTPN11 Q06124 2/20 0.49
MEN1 O00255 1/20 0.49
MAPT P10636 1/20 0.49
CASP3 P42574 1/20 0.49
KMT2A Q03164 1/20 0.49
TRPV1 Q8NER1 1/20 0.49
SENP7 Q9BQF6 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6939271 0.87 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL190719 0.86 CA12 (0.72) CA12CA1CA2CA7CA9
SCHEMBL1147208 0.86 CA12 (0.61) CA12CA1CA2CA7CA9
SCHEMBL29823214 0.86 CA12 (0.61) CA12CA1CA2CA7CA9
SCHEMBL603415 0.84 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL17912414 0.84 ESR1 (0.69) CA12CA1CA2CA7CA9
SCHEMBL39791 0.84 CA12 (1.00) CA12CA1CA2CA7CA9
SCHEMBL29625511 0.84 CA12 (1.00) CA12CA1CA2CA7CA9
SCHEMBL4849260 0.84 MAPT (0.56) CA12CA1CA2CA7CA9
SCHEMBL12780972 0.83 CA12 (0.57) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257355-A1 HYDROXAMIC ACID-CONTAINING COMPOUND, AND PREPARATION METHOD AND USE THEREOF CHINA PHARMACEUTICAL UNIVERSITY (CN) 2023-08-17 US disclosed
WO-2021238328-A1 COMPOUND CONTAINING HYDROXAMIC ACID, AND PREPARATION METHOD THEREFOR AND USE THEREOF 中国药科大学 2021-12-02 WO disclosed
US-20210171883-A1 ANTIVIRAL WIPER FUJIFILM CORPORATION (JP) 2021-06-10 US disclosed
US-11020391-B2 CRMP2 sumoylation inhibitors and uses thereof ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2021-06-01 US disclosed
CN-108289882-B CRMP2 SUMO inhibitors and uses thereof 代表亚利桑那大学的亚利桑那校董会 2020-12-29 CN disclosed
US-20200093822-A1 CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2020-03-26 US disclosed
US-10441586-B2 CRMP2 SUMOylation inhibitors and uses thereof ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2019-10-15 US disclosed
US-20180289700-A1 CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF Arizona Board of Regents on Behalf of the University of Arzona (US) 2018-10-11 US disclosed
EP-2402327-B1 Acetamide compounds as glucokinase activators, their process and medicinal applications IMPETIS BIOSCIENCES LTD (IN) 2018-03-07 EP disclosed
EP-1781661-B1 VASOPRESSIN V1A ANTAGONISTS VANTIA LTD (GB) 2017-06-07 EP disclosed
US-20060014945-A1 N-((hetero)aryl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamides; useful treating AD or common cancers by blocking the activity of gamma-secretase and reducing/preventing the formation of amyloidogenic Abeta peptides and by blocking the Notch signaling pathways that can interfere with cancer pathogenesis. F. HOFFMANN-LA ROCHE AG (CH) 2006-01-19 US disclosed
EP-1577288-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS Eisai Co., Ltd. (JP) 2005-09-21 EP disclosed
US-20050113424-A1 Novel arylamidine derivative or salt thereof TOYAMA CHEMICAL CO., LTD (JP) 2005-05-26 US disclosed
WO-2005025554-A2 DIPEPTIDYL PEPTIDASE IV INHIBITOR JAPAN TOBACCO INC. (JP) 2005-03-24 WO disclosed
EP-1481966-A1 NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2004-12-01 EP disclosed
US-4714774-A ANTIASTHMATIC OR ANTIINFLAMMATORY AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1987-12-22 US disclosed
EP-0181125-A2 Benzoic acid derivatives and their production Takeda Chemical Industries, Ltd. (JP) 1986-05-14 EP disclosed
EP-0180416-A2 Benzoic acid analogues and their production Takeda Chemical Industries, Ltd. (JP) 1986-05-07 EP disclosed
US-4077968-A ANTIINFLAMMATORY, ANTIRHEUMATIC, ANALGESIC, ANTILIPEMIC SHIONOGI & CO., LTD. (JA) 1978-03-07 US disclosed
US-4025528-A ANTIINFLAMMATORY, ANALGESIC, ANTILIPEMIC SHIONOGI & CO., LTD. (JA) 1977-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200093822-A1 CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF SUMO2, SUMO1, SUMO3 CA12 3870/4885CA1 2632/4885CA2 1518/4885
US-20060014945-A1 N-((hetero)aryl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamides; useful treating AD or common cancers by blocking the activity of gamma-secretase and reducing/preventing the formation of amyloidogenic Abeta peptides and by blocking the Notch signaling pathways that can interfere with cancer pathogenesis. BACE1, APP, BACE2 CA12 3144/4885CA1 1569/4885CA2 2044/4885
US-20050113424-A1 Novel arylamidine derivative or salt thereof SLC7A1, NAT1, NACA CA12 3055/4885CA1 4424/4885CA2 1594/4885
US-20210171883-A1 ANTIVIRAL WIPER CGAS, PRKX, PDE4C CA12 2396/4885CA1 2414/4885CA2 1789/4885
US-11020391-B2 CRMP2 sumoylation inhibitors and uses thereof SUMO2, SUMO1, SUMO3 CA12 3870/4885CA1 2632/4885CA2 1518/4885
US-20180289700-A1 CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF SUMO1, SUMO2, SUMO3 CA12 4529/4885CA1 3776/4885CA2 2745/4885
US-20230257355-A1 HYDROXAMIC ACID-CONTAINING COMPOUND, AND PREPARATION METHOD AND USE THEREOF SI, SCD, SMPD1 CA12 1023/4885CA1 122/4885CA2 406/4885
US-10441586-B2 CRMP2 SUMOylation inhibitors and uses thereof SUMO1, SUMO2, SUMO3 CA12 4529/4885CA1 3776/4885CA2 2745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.